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Abstract
Neonatal seizures can be refractory to conventional anticonvulsants, and this may in part be due to a developmental
increase in expression of the neuronal Na
+-K
+-2 Cl
2 cotransporter, NKCC1, and consequent paradoxical excitatory actions of
GABAA receptors in the perinatal period. The most common cause of neonatal seizures is hypoxic encephalopathy, and here
we show in an established model of neonatal hypoxia-induced seizures that the NKCC1 inhibitor, bumetanide, in
combination with phenobarbital is significantly more effective than phenobarbital alone. A sensitive mass spectrometry
assay revealed that bumetanide concentrations in serum and brain were dose-dependent, and the expression of NKCC1
protein transiently increased in cortex and hippocampus after hypoxic seizures. Importantly, the low doses of phenobarbital
and bumetanide used in the study did not increase constitutive apoptosis, alone or in combination. Perforated patch clamp
recordings from ex vivo hippocampal slices removed following seizures revealed that phenobarbital and bumetanide largely
reversed seizure-induced changes in EGABA. Taken together, these data provide preclinical support for clinical trials of
bumetanide in human neonates at risk for hypoxic encephalopathy and seizures.
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Introduction
Neonatal seizures occur most commonly in the setting of
perinatal asphyxia and hypoxic-ischemic encephalopathy (HIE),
and can be resistant to conventional antiepileptic therapies.
Refractory neonatal seizures increase risk of subsequent epilepsy
and neurocognitive morbidity. [1] As there are often few
behavioral manifestations of neonatal seizures, electroencephalo-
graphic (EEG) monitoring is required for diagnosis due to the
occurrence of ‘‘electroclinical dissociation’’. [2–4] Phenobarbital
and phenytoin remains the mainstay of therapy, although there is
little evidence that these agents significantly suppress ongoing
seizure activity or change long-term outcome. The lack of response
to conventional antiepileptic drugs (AEDs) that are otherwise
effective in older children and adults is at least in part due to
maturational differences in factors regulating neuronal network
excitability. [5,6].
The neonatal period is one of heightened synaptic plasticity and
synaptogenesis during brain development. Excitatory ionotropic
glutamate receptors are expressed at higher levels than in later life,
while the expression of classical inhibitory c-amino-butyric acid
(GABA) receptors is significantly lower than adult. [5,7,8] In
normal adult brain, activation of GABAA receptors results in
membrane hyperpolarization due to Cl
2 influx through its ion
channel, and hence are inhibitory. [9] In immature neurons,
however, GABA agonists can cause depolarization due to a net
efflux of Cl
2 through the GABA receptor ion channel, resulting in
neuronal excitation. [10,11] This switch is thought to be in part
due to developmental changes in the expression of two proteins
involved in the maintenance of intracellular Cl
2 homeostasis in
neurons: the Na
+-K
+-2 Cl
2 cotransporter isoform 1 (NKCC1) that
transports Cl
2 into the cell, and the K
+-Cl
2 cotransporter isoform
2 (KCC2) that moves Cl
2 out of the cell. [12] Importantly,
reversal of GABAA receptor polarity appears much later in male
than in female rats, [13,14] but in order to maintain continuity
with our previous studies [15–17] we focus on male rats. In the
immature brain, neuronal intracellular Cl
2 concentrations are
higher than in the adult due to a high NKCC1 expression
coincident with a low KCC2 expression, relative to normal adult
expression patterns. [5,17] The expression of NKCC1 mRNA is
also increased in human forebrain neurons during the perinatal
period, relative to later life. [17,18] In humans, this switch is
thought to occur in utero after NKCC1 peaks between 31–41
postconceptional weeks, whereas in rats this switch occurs near the
end of the second postnatal week, with NKCC1 expression
decreasing after postnatal day (P)14. [17] Other studies have
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appearance of hyperpolarizing GABAA receptors, also occurs
around P14. [13,14] Additionally, the caudal to rostral maturation
of these transporters [4,17] is thought to contribute to the
electroclinical dissociation seen in neonates after treatment with
phenobarbital.
NKCC1 potentially represents an age-specific therapeutic target
and is postulated to contribute to the relative lack of efficacy of
GABAA receptor agonists in newborns. [19] Bumetanide is an
inhibitor of both NKCC isoforms (1 and 2), and is FDA approved
and clinically in use as a diuretic in all age groups, including
neonates, [20,21] as NKCC2 is expressed in the renal tubule cells
in the loop of Henle. However, NKCC2 is not expressed in the
brain and hence bumetanide actions in neurons depend on the
presence of NKCC1, which is broadly expressed throughout the
body, including in neurons. [11] Bumetanide is currently under
study in a Phase I clinical trial as a single add-on therapy in
neonatal seizures in HIE infants 33–44 weeks of age (clinical-
trials.gov/NCT00830531). To further support potential transla-
tion, we performed an evaluation of the efficacy of phenobarbital
alone versus in combination with bumetanide in an established
neonatal rat model of hypoxic encephalopathy and seizures using
behavioral and EEG outcomes. [15,22] To better align with the
clinical trial, we measured serum and brain levels of bumetanide at
seizure suppressing doses using a sensitive stable isotope dilution
liquid chromatography/tandem mass spectrometric (LC-MS/MS)
method. [23] We examined whether seizures acutely altered
NKCC1 and KCC2 protein expression in cortex and hippocam-
pus, or GABAA receptor function in ex vivo hippocampal slices
following hypoxia-induced seizures (HS) in immature rats. Finally,
as some AEDs induce apoptosis in developing cortex, [24] we
evaluated apoptosis after seizure-suppressing doses of phenobar-
bital and bumetanide.
Methods
Ethics Statement
All procedures were in accordance with the guidelines of the
National Institutes of Health’s Guide for the Care and Use of Laboratory
Animals. The protocol was approved by the Animal Care and Use
Committee at Children’s Hospital Boston (protocol number: 11-
05-1952R). We made all efforts to minimize animal suffering and
the number of animals used.
Animals
Male Long Evans rat pups (Charles River Laboratories, MA)
were maintained in a temperature-controlled animal care facility
with a 12 hr light-dark cycle.
Hypoxia-induced Seizures and Drug Administration
P10 rat pups were exposed to nonlethal graded global hypoxia
for 15 min in an airtight chamber as previously described. [15,22]
Briefly, oxygen concentration was maintained at 7% for 8 min,
5% for 6 min, and 4% for 1 min before termination of hypoxia.
Each animal was scored for the number of tonic-clonic seizures
during the 15 min hypoxic episode. Littermate controls were
separated from their dams and kept at room air for the duration of
the experiment. Body temperature was maintained between 32–
34uC, and all rats were returned to their dams within two hr.
Prior to seizure induction, phenobarbital (15 mg/kg) and/or
bumetanide 0.15 mg/kg (low dose) or 0.3 mg/kg (high dose) or
vehicle were administered to P10 rat pups (18–22 g) by
intraperitoneal (i.p.) injection. Phenobarbital was diluted in 0.9%
saline, and bumetanide (MP Biomedical) was dissolved in DMSO,
then diluted in 0.9% saline. Phenobarbital and bumetanide were
administered as separate injections at intervals 30 and 15 min
prior to hypoxia, respectively. Five treatment groups and one
vehicle group were tested: phenobarbital alone, bumetanide alone
(low or high dose), and phenobarbital in combination with either
of the two bumetanide doses. Rats in the phenobarbital only and
bumetanide only groups received an additional vehicle i.p.
injection (DMSO in 0.9% NaCl or 0.9% NaCl) of the same
volume they would have received if they were in a combined
treatment group. Vehicle-treated rats received two vehicle i.p.
injections (DMSO in 9% NaCl and 0.9% NaCl) of the same
volume as those in the combined treatment group.
Behavioral and Electrographic Assessment of Seizures
during Hypoxia
Seizures during hypoxia were videotaped and reviewed by an
investigator blind to treatment, and scored for the number and
cumulative duration of tonic-clonic seizures during hypoxia. A
subgroup of rats was monitored by video-electroencephalogram
(video-EEG) before, during, and after hypoxia. Continuous video-
EEG was acquired using three thin silver/silver-chloride Teflon
coated subcutaneous wire electrodes (SWE) for a total of 90 min
for each rat (Fig. 1A). [15,25] A reference contact was positioned
over the dorsal snout at midline, with two active contacts in the
scalp over the parietal regions bilaterally. A fourth electrode was
placed in the skin of the torso to record EKG, and a ground
electrode was placed in the lower back. SWE implantation causes
only minimal, momentary pain, and is well tolerated by the rat
pups. [15] Video-EEG monitoring was performed in a Plexiglas
recording chamber, and animals were allowed free movement
around the recording chamber.
Analysis of EEG was performed on amplified (x10,000) signals
digitized at 200 Hz, filtered using a digital 32-channel EEG-
recording apparatus from Stellate Systems Inc. (Natus Medical
Systems, CA), and displayed in a referential montage for post hoc
analysis by visual inspection. An investigator blind to treatment
conditions reviewed EEG recordings to assess seizure activity.
Seizures were defined as electrographic seizures recorded from
both hemispheres, only when they consisted of paroxysmal
rhythmic spikes of high amplitude, diffuse frequency of $ 8H z
lasting $ 3 s (Figure 1), and were accompanied by a behavioral
correlate, such as head bobbing, wet dog shakes, and tonic-clonic
movements, similar to previous report. [15] EEG power analysis
was performed using Persyst software (Persyst Inc. Tucson, AZ) on
5 min epochs during the baseline pre-hypoxia and then during
hypoxia exposure (see Methods S1). Time frequency analysis of
EEG power was carried out by consecutive 10-second Fast-Fourier
transform (FFT) analysis. EEG was filtered using 1 Hz high-pass
and 60 Hz low-pass filtering to remove ambient noise, binned in
20 s intervals, and power within the epoch was determined. The
summed power was then calculated for frequency bands 4–12 Hz,
and 12–32 Hz.
Assessment of Serum and Brain Bumetanide
Concentrations
Control rats were treated with phenobarbital and bumetanide
(0.15 or 0.3 mg/kg), anesthetized (100 mg/kg pentobarbital), and
perfused transcardially with 0.9% saline at 10, 30, 60, and
120 min following bumetanide injection. An additional group of
rats was also exposed to global hypoxia prior to sacrifice, using the
treatment paradigm described earlier. The 10 min group could
only be collected for control rats due to the treatment paradigm.
Blood was collected by cardiac puncture before perfusion, then
Phenobarbital and Bumetanide in Neonatal Seizures
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perfusion, halved along the sagittal midline, then frozen. All brains
were visually inspected for signs of blood during collection. In the
occasional cases where brain perfusion was incomplete, serum and
brain tissue from those animals was excluded from all further
analysis.
Levels of bumetanide in serum and brain were analyzed by LC-
MS/MS, using a previously described method. [23] The lower
limit of quantitation for the assay was 1 ng/ml with an accuracy of
95%. [23] Briefly, 15 ml of serum were mixed with 135 mlo f
internal standard (0.2 mMD 5-bumetanide in acetonitrile), then
vortexed for 1 min to precipitate protein, and centrifuged for
5 min at 16,200 relative centrifugal force. For brain samples, tissue
from one hemisphere (,0.5 g) was homogenized in 270 mlo f
internal standard and additional acetonitrile, then centrifuged for
10 min at 16,200 relative centrifugal force. Supernatant was
analyzed using a Waters Quattro Premier mass spectrometer
equipped with an electrospray ionization source, and a Waters
Acquity UPLC system (Waters Corp., MA) with an Atlantis T3
column (Waters Corp., 100 6 2.1 mm, 3 mm). Selected reaction
monitoring (SRM) transitions were monitored for both bumeta-
nide and D5-bumetanide. Additionally, the ratio of bumetanide
concentration in brain to that in serum was calculated for each
animal as a relative measure of drug elimination rates from the
brain and serum. Of the 51 rats tested, three (2 control, 1 hypoxic)
had brain levels below the assay’s lower limit of quantitation
(,0.01 ng/g) [23] and were therefore excluded from the analysis.
Assessment of Constitutive Cell Death After Drug
Administration
Many commonly used antiepileptic drugs, including high doses
of phenobarbital, acutely increase constitutive apoptosis in the
developing rodent brain following a single dose, [24] yet Bittigau
et al previously demonstrated that phenobarbital doses below
Figure 1. EEG recording schedule and representative electrographic seizure. (A) After SWE implantation, continuous video-EEG was
recorded from each rat for a total of 90 min. Recordings began 45 min before the start of hypoxia and ran an additional 30 min after the termination
of hypoxia. Phenobarbital (pheno) was injected 30 min before hypoxia, and was followed by bumetanide (BMX) injection 15 min later. Epochs
totaling 5 min were selected from the recording during hypoxia for EEG power analysis. Random selections from the baseline recording were used as
controls. (B) Representative baseline EEG recording from a P10 rat prior to treatment and exposure to graded global hypoxia. (C) Typical
electrographic seizure recorded from one hemisphere (other hemisphere not shown) in a P10 rat during the course of hypoxia. All electrographic
seizures were accompanied by behavioral automatisms. Arrow indicates seizure onset. Insets of the EEG trace in an expanded time scale show seizure
initiation, followed by a progressive buildup in spikes of increasing frequency and amplitude, regular tonic spike wave discharges, and post-ictal
slowing following seizure termination.
doi:10.1371/journal.pone.0057148.g001
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effects of the aforementioned dosing of phenobarbital (15 mg/kg)
and bumetanide (0.3 mg/kg), either alone or in combination, on
constitutive cell death. A vehicle-treated rat was used as a negative
control, and a rat treated with a single 1 mg/kg i.p. dose of the
NMDA receptor antagonist, dizocilpine (MK-801), which has
previously been shown to increase constitutive apoptosis, [27] was
used as a positive control. At 48 hr after treatment, rats were
anesthetized (100 mg/kg pentobarbital) and perfused transcar-
dially with PBS, followed by 4% paraformaldehyde. Brains were
removed and post-fixed overnight with 4% paraformaldehyde in
PBS, and then cryoprotected in 30% sucrose in PBS. 16 mm
coronal sections were cut on a cryostat (Leica Microsystems,
Germany), collected onto slides, and stored at 220uC until
needed. Constitutive cell death was determined by terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) with an anti-fluorescein antibody conjugated with a
peroxidase reporter enzyme (Roche, IN), and visualized with 3,39-
Diaminobenzidine (DAB, Vector Laboratories Inc., CA). Sections
were lightly counterstained with Methyl Green to enhance tissue
visualization, then rapidly dehydrated through to 100% ethanol
prior to clearing in Histoclear, and coverslipping with DPX
mounting medium (Fluka Biochemika, Switzerland).
Coronal sections in the region of the mid-dorsal hippocampus
(2.8–3.1 mm from Bregma, 2.6–3.0 mm lateral to midline) [28]
were examined, allowing assessment of multiple brain regions in
one section. Transmitted light images were obtained on a Zeiss
Axioscope microscope, using a Spot digital camera and Advanced
4.5 software (Spot Imaging Solutions, MI). Non-overlapping low
power photomicrographs were taken of parietal cortex, hippo-
campus, thalamus, caudate-putamen, and amygdala. The total
area examined for each animal varied by region from about
1.7 mm
2 for caudate putamen to over 4 mm
2 for thalamus. Brain
regions were analyzed separately and as a combined area
(15 mm
2) for the number of TUNEL-positive cells. TUNEL
positive cells were evident as darkly stained pyknotic nuclei within
a background of healthy appearing cells counterstained with
methyl green. Parietal cortex from a rat treated with MK-801 was
used as a positive control.
Western Blot Analysis of NKCC1 and KCC2 Expression
Following Seizures
Cortex and hippocampal tissue from rats sacrificed at 1, 12, 24,
48, and 168 hr following HS was dissected over cold PBS and
membrane protein fractions were obtained, as previously de-
scribed. [29] Naı ¨ve littermate rats that had not been exposed to
hypoxia were used as controls. Briefly, tissue samples were
homogenized over ice in a sucrose buffer containing one Complete
Mini, Ethylenediaminetetraacetic acid (EDTA)-free protease
inhibitor cocktail tablet (Roche) per 10 ml of buffer. Membrane
fractions were collected and resuspended in lysis buffer. Total
protein amounts were measured using the Bradford protein assay
(Bio-Rad, CA), and samples were diluted for equal amounts of
protein in each sample. Samples were run on 4–20% gradient
Tris-HCl gels (Bio-Rad) and transferred onto polyvinylidene
difluoride (PVDF) membranes via a semi-wet system (Invitrogen
iBlot, Life Technologies Corp, NY). Membranes were blocked for
1 hr in 5% non-fat dry milk in Tris-buffered saline with 0.1%
Tween 20 (Boston Bioproducts) before overnight incubation in
primary antibody (NKCC1 (T4) at 1:1000, Hybridoma Bank;
KCC2 at 1:500, Upstate; actin at 1:10000, Invitrogen). Blots were
then incubated for 1 hr in horseradish-peroxidase conjugated
secondary antibodies (0.1 g/ml anti-rabbit IgG, 0.5 g/ml anti-
mouse IgG, Invitrogen). Protein bands were visualized by
chemiluminescence using the Image Reader LAS 3000 digital
system and Image Gauge 4.0 software (Fuji Film Life Sciences,
Japan). The optical densities (OD) for NKCC1 and KCC2 were
first normalized to actin, averaged for each time point, and then
expressed as a percentage of the control mean values from samples
run on the same blot. We also calculated the ratio of NKCC1 to
KCC2 from the normalized individual values (% of control
means), as a measure of hypoxia-induced changes from normal
expression patterns.
Perforated Patch Clamp Recordings from Hippocampal
Slices
Hippocampal slices were prepared at 24 hr after HS as
previously described. [30,31] Briefly, rat pups were decapitated
24 hr after HS. Littermate rats that had not been exposed to
hypoxia were used as normoxic controls. Brains were rapidly
removed and dissected in oxygenated (95% O2–5% CO2), ice-cold
(2–5uC) cutting solution containing 210 mM sucrose, 2.5 mM
KCl, 1.02 mM NaH2PO4, 0.5 mM CaCl2, 10 mM MgSO4,
26.19 mM NaHCO3, and 10 mM D-glucose (pH 7.4). Coronal
hippocampal slices were sectioned at 300 mm from the middle
third of the hippocampus using a vibratome (Lecia VT1000S,
Leica). For electrophysiological recording, slices were transferred
to a chamber containing oxygenated artificial cerebral spinal fluid
(ACSF) containing 124 mM NaCl, 5 mM KCl, 1.25 mM
NaH2PO4, 2 mM CaCl2, 1.2 mM MgSO4, 26 mM NaHCO3,
and 10 mM glucose (pH 7.4 ) at 35uC for 30 min and thereafter at
room temperature for at least 1 hr before use.
Gramicidin perforated patch clamp recordings were used in
order to maintain the endogenous intracellular Cl
2 concentration,
as per our previously published protocol. [32] Electrodes for
perforated-patch clamp recordings were prepared from thin-
walled glass pipettes using a model P-87 micropipette puller (Sutter
Instrument Co., CA). The electrode was filled with a KCl-based
internal solution containing 150 mM KCl, and 10 mM HEPES
(pH 7.2, adjusted with potassium hydroxide, 280–290 mOsm/kg).
Gramicidin was dissolved in DMSO at 40 mg/ml, and then added
to the pipette solution to a final concentration of 80 mg/ml.
Electrodes were back filled with gramicidin-containing solution,
then tip filled with gramicidin-free solution. The resistance of the
patch electrode ranged from 3 to 6 MV. Perforated-patch
recordings were made using an Axopatch 200A amplifier (Axon
Instruments, CA) with a sampling frequency of 10 kHz after low-
pass filtering at 1 kHz, using pClamp9 software (Clampex,
Molecular Devices, CA). After the cell-attached formation, series
resistance was monitored with 5 mV hyperpolarizing pulses. It
typically took about 30 min for the series resistance to drop to 30–
70 MV and stabilize.
GABA (100 mM) was briefly (100–200 ms) puffed onto the
dendrites of the recorded neurons via a patch-type electrode using
a valve-controlled pressure application system (Picospritzer II;
Parker Hannifin Corporation, OH). We allowed at least 25 s
between GABA applications. GABAA receptor–mediated currents
were pharmacologically isolated by application of 10 mM NBQX,
and 100 mM DL-AP5 to block AMPA and NMDA receptors. The
reversal potentials for the GABA-induced currents (EGABA) were
determined by varying the holding potential of the recorded
neuron in 10 mV increments, and then measuring peak amplitude
of the GABA-activated currents. To parallel the in vivo treatment,
phenobarbital (100 mM) and bumetanide (10 mM) were applied
alone and in combination to test their effects on EGABA. Data were
collected 10 min after drugs were applied, and each drug was
applied for a total of 15 to 20 min. Recordings for each condition
were compared to control recordings obtained prior to drug
Phenobarbital and Bumetanide in Neonatal Seizures
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performed using Clampfit 9 (Molecular Devices).
Statistical Analysis
Group measures are expressed as mean 6 standard error of the
mean (SEM); error bars also indicate SEM. Statistical analysis for
differences between group means was performed using t-test and
one-way analysis of variance (ANOVA) for multiple group
comparisons.
Results
Acute Hypoxia-induced Behavioral and EEG Seizures
Consistent with previous studies, [15,22] exposure to graded
global hypoxia induced acute seizures in 95% of the vehicle-
treated rats (38 of 40 rats $ 5 seizures). Seizures were
characterized by head bobbing, wet dog shakes, and tonic-clonic
head and limb movements. During the 15 min hypoxic episode,
vehicle-treated rats averaged 11.860.7 seizures, with an average
cumulative seizure duration of 229616.3 s (Fig. 2A, B).
To confirm that the observed behavioral events were in fact ictal
EEG activity, video-EEG and FFT analysis was performed in a
subgroup of rats during hypoxia. Of the 201 seizures recorded
from all treatment groups, 52.7% were between 3 and 15 s in
duration, and 24.9% were 15–30 s in duration. Seizure duration
ranged from 3–113 s, with an average duration of 21.861.48 s,
and all seizures were accompanied by the behavioral automatisms
described earlier. FFT analysis was performed on frequency bands
4–12 Hz and 12–32 Hz, however, significant changes were only
seen in the 4–12 Hz band (12–32 Hz data not shown).
Effect of Combination Treatment on Hypoxia-induced
Behavioral Seizures and EEG Ictal Activity
Treatment with phenobarbital alone (n=33) prevented seizures
in only 23% during hypoxia (Fig. 2A, B). Compared to the vehicle-
treated HS group (n=38), phenobarbital reduced average seizure
number from 11.860.7 to 6.861.0 (p,0.001), and cumulative
seizure duration was reduced from 229616.3 s to 122620.8 s
(p,0.001). Low dose bumetanide (0.15 mg/kg) alone had very
little effect on seizures in our model (n=18, 12.361.3,
251630.8 s), and monotherapy with the higher dose (0.3 mg/
kg, n=15) only moderately attenuated seizure activity (7.161.4,
p,0.01; 158637.3 s). In contrast, the combination of phenobar-
bital with low dose bumetanide (n=35) reduced seizure incidence
by approximately 75% compared to vehicles (3.860.9,
61.3616.1 s, p,0.001), while combination with the high dose
further decreased seizure activity by 85% from vehicle-treatment
(n=25, 1.660.6, 38.5617.0 s, p,0.001), and ,75% from
phenobarbital alone (p,0.01). The low and high dose combined
treatments completely suppressed seizures in 46% and 64% of the
rats treated, respectively.
FFT analysis was used to quantitate differences in ictal activity
between treatment groups. Vehicle-treated rats (n=4) showed
increased spectral power between 4–12 Hz (summed power
43.363.7 mV) during seizures (Fig. 2C) compared to the baseline
EEG epochs (22.761.3 mV, p,0.01). When administered alone,
no significant effect on EEG power was seen with phenobarbital
(n=5, 56.868.1 mV), low dose bumetanide (n=3,
45.8467.4 mV), or high dose bumetanide (n=5, 47.165.5 mV),
as compared to vehicle. While combination of phenobarbital with
low dose bumetanide appeared to have only a modest effect (n=3,
30.069.4 mV), its combination with high dose bumetanide
significantly reduced summed power compared to vehicle (n=4,
Figure 2. Seizure number, cumulative duration, and EEG power
attenuation in rats treated with phenobarbital and bumeta-
nide. The number of hypoxia-induced seizures (A), and cumulative
seizure duration (B) were plotted for each treatment group. Vehicle-
treated rats (n=38) averaged 11.860.7 seizures, with an average
cumulative seizure duration of 229616.3 s. Treatment with phenobar-
bital (pheno) reduced seizure incidence by approximately 50% (n=33,
6.861.0, 122620.8 s), but did not completely attenuate activity. The
combination of phenobarbital and 0.15 mg/kg bumetanide (pheno
+0.15 mg/kg BMX) reduced seizure incidence by approximately 75%
compared to vehicles (n=35, 3.860.9, 61.3616.1 s), and was more
effective than phenobarbital alone. The higher dose (pheno +0.3 mg/kg
BMX) was even more effective, decreasing seizure activity by ,85%
from vehicles (n=25, 1.660.6, 38.5617.0 s), and ,75% from pheno-
barbital. (C) FFT analysis revealed increased spectral power between 4–
12 Hz during seizures (vehicle). The average summed power between
4–12 Hz was plotted for each treatment group. Treatment with
phenobarbital (n=5, 56.868.1 mV), bumetanide (low dose: n=3,
45.8467.4 mV; high dose: n=5, 47.165.5 mV), and the combination of
phenobarbital and low dose bumetanide (n=3, 30.069.4 mV) had little
effect on summed power at these frequencies. However, in rats treated
with the high dose combination (n=4, 24.663.0 mV) summed power
was reduced to levels similar to pre-hypoxia baseline EEG recordings
(control). Mean 6 SEM. Error bars indicate SEM. *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0057148.g002
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recordings.
Effects of Phenobarbital and Bumetanide on Constitutive
Cell Death during Development
In vehicle-treated rats (n=10) the distribution of TUNEL
positive cells was sparse, consistent with prior reports, ranging
between 1.460.14 to 1.960.21 cells/mm
2 in 5 different anatom-
ical regions: parietal cortex, amygdala, caudate putamen, hippo-
campus, and thalamus. [24,27] Neither phenobarbital (n=11) nor
high dose bumetanide (n=11), administered separately or in
combination (n=8), caused a significant increase in apoptosis
above background levels seen in vehicle-treated parietal cortex
(p=0.183), amygdala (p=0.727), caudate putamen (p=0.317),
hippocampus (p=0.724), or thalamus (p=0.096) (Figure 3).
Comparison of cumulative apoptosis within all 5 regions also
revealed no alterations in apoptosis with the different drug
treatments (p=0.129).
Temporal Profile of Serum and Brain Bumetanide Levels
Following Treatment
Bumetanide serum and brain levels were determined in 51 rat
pups (n=28 controls, n=23 HS, Tables S1, S2). Bumetanide was
rapidly eliminated from serum (Fig. 4A, B), with an average half-
life of 29.9 min at the low dose and 31.6 min at the high dose in
controls, longer than the 10 min half-life reported in adult rats.
[33] Average serum concentrations of 20867.1 and
340624.9 ng/ml were determined 10 min after injection (n=3,
3) and fell to 13.162.7 and 25.864.0 ng/ml at 120 min (n=2, 4)
for the low and high dose, respectively. Similar levels were seen in
treated HS rats, peaking at 152623.1 and 182616.9 ng/ml at
30 min (n=4, 4) and falling to 20.165.4 and 30.261.5 ng/ml at
120 min (n=3, 3) for the low and high dose, respectively. Due to
the absence of the 10 min group in the hypoxic rats, however,
half-lives could not be determined for this group as three data
points was insufficient to obtain an accurate line fit.
While still above the lower limit of detection of the assay
(0.1 ng/ml), [23] brain levels were very low, with peak levels in
control pups at 0.7660.07 and 1.2260.08 ng/g 10 min after
injection for the low and high dose, respectively (Fig. 4C, D).
These brain levels were on average higher in rats exposed to
hypoxia than in controls (data not shown), potentially indicating
enhanced drug uptake due to an increase in blood brain barrier
permeability or increased blood flow. Bumetanide appeared to be
eliminated more slowly from the brain as evidenced by the
brain:serum concentration ratio (Fig. 4E, F), which more than
doubled in both control and hypoxic rats.
Transient Changes in NKCC1 and KCC2 Expression
Following Neonatal Seizures
The effects of hypoxic seizures on the relative expression of
NKCC1 and KCC2 were assessed by western blotting in cortical
and hippocampal tissue removed at 1, 12, 24, 48, and 168 hr post-
HS. In the cortex, HS caused an initial decrease in the expression
of NKCC1 relative to KCC2 (n=7, 0.6660.09 fold, p=0.003),
followed by a nearly two-fold increase between 12 and 24 hr post-
hypoxia (12 hr: n=7, 1.7160.27 fold, p=0.046; 24 hr: n=8,
1.8360.26 fold, p=0.008) before stabilizing to levels similar to
controls (Figure 5). In the hippocampus, the ratio of NKCC1 to
KCC2 underwent a transient increase 12 hr after HS, rising
1.3960.09 fold (n=8, p=0.016) before returning to normal levels.
Phenobarbital and Bumetanide Reversed Depolarized
EGABA in CA1 Neurons from ex vivo Slices Removed at
24 hr post-HS
CA1 hippocampal neurons in slices removed from rat pups
24 hr post-HS showed a significant positive shift in EGABA (n=9,
258.5862.72 mV, Figure 6) as compared to control slices (n=7,
267.7063.26 mV, p,0.05), with no changes in resting mem-
brane potential between the two groups (p.0.05). We next
compared the effects of phenobarbital (100 mM) alone or in
combination with bumetanide (10 mM) to control conditions
(n=6, Figure 7). Phenobarbital alone increased GABA-evoked
current amplitude, but had no effect on GABA reversal potential
(258.4661.58 mV) compared to control conditions
(258.6161.28 mV, p.0.05). In contrast, the combination of
phenobarbital with bumetanide significantly decreased reversal
potential (264.5362.30 mV, p,0.05) to baseline values seen in
naı ¨ve age-matched littermates (p.0.05, Fig. 6A1). These data
suggest GABA-mediated bumetanide-sensitive excitation in neu-
rons post-seizure.
Discussion
The present study provides preclinical support for the use of
bumetanide as an add-on therapy in the treatment of neonatal
seizures. Similar to human neonates, the second postnatal week of
life in the rat is characterized by high expression of NKCC1 in
cortical and hippocampal neurons, which could contribute to
resistance to GABA agonist anticonvulsants. [17] In a clinically
relevant model of hypoxia-induced seizures, the combination of
the NKCC1 inhibitor, bumetanide, and phenobarbital showed
superior efficacy to phenobarbital alone. Systemic administration
of bumetanide resulted in a dose-dependent increase in both
serum and brain concentrations. Seizures in the immature rat
transiently increased the NKCC1:KCC2 ratio, and hippocampal
slices prepared from rats following seizures exhibited a shift in
GABA reversal potential consistent with NKCC1-mediated Cl
2
intracellular flux, which was reversed by combined application of
phenobarbital and bumetanide. Unlike other AEDs, the combi-
nation of bumetanide and low dose phenobarbital used here does
not appear to increase constitutive apoptosis during the second
postnatal week, [24,26,27,34] suggesting that combination therapy
may provide more efficacy and safety than high dose phenobar-
bital alone.
Neonatal Seizure Therapies
The standard of care for neonatal seizures is treatment with
high doses of phenobarbital and/or phenytoin, yet studies have
failed to show significant efficacy. [2,6,35] Although seizures are
often only present for a few days postnatally in the case of birth
asphyxia and HIE, the consequences of neonatal seizures can be
severe. [6,36] Unique age-specific mechanisms of seizure gener-
ation in the newborn brain are likely to underlie the refractory
nature of neonatal seizures, [37] and include the heightened
expression of excitatory glutamate neurotransmitter receptors, and
a relative under-expression of inhibitory GABA receptors com-
bined with low GABA synthesis. [6] While agents that inhibit the
AMPA subtype of the glutamate receptor, such as topiramate or
talampanel, are protective in neonatal seizure and hypoxia/
ischemia models, [5,38–40] the use of these agents has yet to be
effectively translated to clinical trials due to their lack of parenteral
formulations that are necessary in these critically ill neonates.
The NKCC1 inhibitor, bumetanide, is FDA approved for use as
a diuretic and has been used in neonates safely for decades for this
indication. [20,21] Most recently, a Phase I/II dose escalation
Phenobarbital and Bumetanide in Neonatal Seizures
PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e57148Figure 3. Phenobarbital and bumetanide, singly or in combination, did not increase constitutive cell death in P10 rat pups.
Representative photomicrographs and magnified insets of TUNEL staining on 16 mm coronal sections of parietal cortex 48 h after treatment with (A)
MK801 (positive control), (B) vehicle (DMSO in 0.9% saline) (n=10), (C) phenobarbital (n=11), (D) high dose bumetanide (n=11), or (E) combined
phenobarbital and high dose bumetanide (n=8). Sections were lightly counterstained with methyl green. Pictures were taken at low power to
maximize scoring, and magnified insets show detail. Other regions examined were amygdala, caudate-putamen, hippocampus, and thalamus.
Apoptotic cells can be seen as dark pyknotic nuclei (arrows denote examples). No treatment significantly increased constitutive apoptosis compared
to vehicle when analyzed within each region or in the total area (p=0.129). A P7 rat pup treated with MK801 served as a positive control, and showed
numerous apoptotic neurons clustered in layer II but also in other cortical layers. Scale bar=200 mm (inset scale bar=35 mm).
doi:10.1371/journal.pone.0057148.g003
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phenobarbital in infants with neonatal seizures (clinicaltrials.gov,
NCT00830531) is being conducted to more specifically address
bumetanide safety in its use as an AED. The population of this
safety study are infants with HIE or stroke, and hence the present
preclinical study was performed to examine efficacy of bumetanide
in HS in rodents to more closely resemble the human disease state.
While several studies have demonstrated efficacy of bumetanide in
chemoconvulsant models of seizures in immature rats as well as in
in vitro hippocampal preparations, [16,17] its efficacy and safety
alone or in combination with phenobarbital have never been
tested in a clinically relevant model of HIE-induced seizures, nor
has there been any direct assessment of bumetanide levels in serum
and brain.
Efficacy of Combination Therapy with Phenobarbital and
Bumetanide
The present study shows that phenobarbital alone, at a dose
effective in adult rodents, [41] has only modest anticonvulsant
activity in our neonatal rat model of HS. This is consistent with the
limited efficacy seen in human studies. [35] Addition of the
0.15 mg/kg low bumetanide dose used in prior studies [17],
however, resulted in a significant improvement, while addition of
higher doses of 0.3 mg/kg resulted in almost complete attenuation
of seizure activity. In contrast to prior reports, [17] [42]
bumetanide alone had little to no efficacy in this model, suggesting
that the relative role of basal NKCC1 expression may differentially
regulate the model-dependent seizure susceptibility. Indeed the
current Phase 1 trial is that of a combination of bumetanide with
phenobarbital (clinicaltrials.gov, NCT00830531). Previous studies
have demonstrated that behavioral seizures and EEG changes are
correlated with an increase in EEG power, [15,43,44] which can
be reduced with certain anticonvulsants. [15,44] In our study, FFT
analysis revealed a similar correlation between EEG power and
seizure frequency. Neither phenobarbital alone nor bumetanide
had any effect on EEG power, however, the combination of
phenobarbital and 0.3 mg/kg bumetanide was able to reduce
power to levels resembling baseline recordings. Taken together,
these results support our prior reports on kainate seizures in
neonatal rats, [17] and suggest that phenobarbital in combination
with bumetanide, especially at the higher dose, exhibits an acute
synergistic effect on seizures.
While the present study demonstrates an acute effect on
symptomatic hypoxic seizures, future studies will need to address
whether these doses alter long-term cognitive and epilepsy
outcomes. We have recently shown that other agents that suppress
activity-dependent signaling administered around the seizure can
Figure 4. Bumetanide serum and brain levels, and brain:serum concentration ratios in control and hypoxic rats. Serum bumetanide
levels in rats after hypoxia-induced seizures (HS, B) and in littermate controls (A) were plotted for the low (0.15 mg/kg) and high (0.3 mg/kg)
bumetanide doses. In controls, average elimination half-lives of 29.9 min (low dose) and 31.6 min (high dose) were calculated using GraphPad Prism.
Best-fit values were calculated assuming a one-phase exponential decay. Brain levels for control (C) and HS (D) rats were plotted for the low and high
bumetanide doses. Plots of the brain:serum concentration ratios (E, F) show that bumetanide was eliminated more slowly from the brain than from
serum. Mean 6 SEM. Error bars indicate SEM.
doi:10.1371/journal.pone.0057148.g004
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this model. [45] It is possible that acute seizure suppression with
bumetanide and phenobarbital may have comparable effects
either due to a direct role of NKCC1 in brain maturation, or
secondary to more non-specific seizure suppressing effects. Indeed,
a recent report showed that bumetanide in combination with
phenobarbital, when used in addition to hypothermia, shows
superior neuroprotective efficacy for acute and long term
outcomes in a rodent neonatal stroke model. [46] Additionally,
recent reports indicate that long-term treatment may decrease
autistic behavior in human infants without side effects. [47] These
reports suggest a more expansive role for bumetanide in treating
the long-term consequences of neonatal seizures, which we hope to
Figure 5. Seizure-induced alterations in NKCC1 and KCC2
protein levels. Using Western Blot, NKCC1 and KCC2 protein levels
were assessed in cortical and hippocampal tissue obtained from P10
rats at 1, 12, 24, 48, and 168 hr after hypoxia-induced seizures (HS), and
compared to age-matched littermate controls. Optical densities for
NKCC1 and KCC2 were normalized to actin, averaged for each time
point, and then the average expression in hypoxic animals was
normalized to that in control animals. NKCC1 (A) and KCC2 (B)
expression was plotted as a percent of control (dotted line). NKCC1
increased transiently at 24 hr post-HS (n=8, 138610.5% control,
p=0.005) in cortex, but showed no significant change in hippocampus.
KCC2 expression increased early at 1 hr post-HS (n=4, 14069.6%
control, p=0.004) in hippocampus, with a later cortical increase 24 hr
post-HS (n=8, 8166.7% control, p=0.025). The normalized ratio of
NKCC1 to KCC2 (C) was then calculated as a measure of changes in the
relative expression of NKCC1 and KCC2 from normal expression
patterns. In the cortex, the ratio of NKCC1 to KCC2 initially decreased
1 hr after seizures (n=7, 0.6660.09 fold, p=0.003), and then increased
at 12 and 24 hr (12 hr: n=7, 1.7160.27 fold, p=0.046; 24 hr: n=8,
1.8360.26 fold, p=0.008), as compared to controls. In the hippocam-
pus, NKCC1/KCC2 was significantly higher at 12 hr (n=8, 1.3960.09
fold, p=0.016), as compared to controls. (D) Representative western
blot images for NKCC1, KCC2, and actin protein levels in cortex (top)
and hippocampus (bottom). C=control; HS=hypoxic seizures. Mean 6
SEM. Error bars indicate SEM.*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0057148.g005
Figure 6. Hypoxic seizures induce a positive shift in EGABA in
hippocampal CA1 pyramidal neurons. Representative recordings
of GABA-evoked currents in CA1 neurons from normoxic control
hippocampal slices (A1) versus slices removed at 24 hr post-hypoxic
seizures in vivo at P10 (A2). (B) Current–voltage curves for the
recordings shown in A1 and 2. The data points were fitted with a
straight line. (C) Summary of the reversal potential of the GABA-evoked
currents in CA1 pyramidal neurons in slices removed after hypoxic
seizures (n=9, 258.5862.72 mV) compared with control slices (n=7,
267.7063.26 mV). Error bars indicate SEM. *p,0.05.
doi:10.1371/journal.pone.0057148.g006
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Evidence for Enhanced NKCC1 Expression and Functional
Depolarizing GABA Currents in Hypoxia-induced Seizures
The relative enhanced expression of NKCC1 in the immature
rodent and human brain as compared to adult [10,17,48] has been
thought to contribute to enhanced seizure susceptibility and the
refractoriness of neonatal seizures to GABA agonists, such as
phenobarbital. [49] Neuronal activity can modulate NKCC1
expression and consequent EGABA, [50] and seizure-induced
NKCC1 expression following status epilepticus [51] has been
postulated to contribute to epileptogenesis in adult rats. [33] Here
we show that NKCC1 is transiently increased in hippocampus and
cortex within the first 24 hr post-seizure, suggesting that seizures
may further increase the level of GABAA receptor mediated
depolarization. NKCC1 can be upregulated both transcriptionally
following excitotoxic insults and post-translationally through
phosphorylation at its Thr-212 and Thr-217 sites on the
cytoplasmic N terminus. [52].
In intact hippocampi prepared from immature rats or mice
following chemoconvulsant-induced seizures, intracellular Cl
2
progressively increases over a matter of hours, with a reversal of
GABAA receptor-mediated currents, a simultaneous increase in
NKCC1 neuronal membrane expression, and a progressive
decrease in the efficacy of phenobarbital. [50] Indeed, here we
show that CA1 neurons in hippocampal slices removed from rats
at 24 hr post-HS exhibit a shift in GABA reversal potential that
can be reversed with application of phenobarbital and bumeta-
nide. Likewise, recurrent kainate-induced seizures in immature rat
brain have been shown to be associated with progressive increases
in NKCC1 activity, [50] suggesting that this shift may be a
generalized response in immature neurons.
Dose-dependent Increases in Brain and Serum
Bumetanide Levels in Control and Hypoxic Neonatal Mice
As the bumetanide doses in this rat model are similar to those
being used in humans in the Phase I/II pharmacokinetic and
safety study, an evaluation of pharmacokinetics was justified in the
rat model using the same assay as in the human trial. [23] We
show here that bumetanide levels are indeed detectable in both
brain and blood following i.p. administration, and that the half-life
in serum is approximately 20 min longer than the average half-life
of the drug in adult rats for both doses. [33] Serum levels obtained
here in the P10 rat with 0.15 and 0.3 mg/kg were in the 200–
350 ng/ml range (within the diuretic range in human infants) [53],
while plasma levels reported in the adult following much higher
15 mg/kg doses were only 27 mg/ml. [33] In adult animals, peak
brain levels with this higher dose of bumetanide (15 mg/kg) were
in the 0.1–0.3 mg/g range, and when lower doses were used the
brain levels were below the detection threshold (0.1 mg/g) for the
assay used. [33] Here, we employed a more sensitive LC-MS/MS
assay with a lower detection range, [23] which was required since
in the present study the administered doses were over ten-fold
lower than those used by Brandt, et al. [33] We showed brain
levels following the 0.3 mg/kg dose peaked at 1.2 ng/ml in P10
control rats, with a trend towards slightly higher brain concen-
trations in the HS rats, suggesting a seizure-associated increase in
blood brain barrier permeability or increased blood flow. These
Figure 7. The combination of phenobarbital and bumetanide alter EGABA in CA1 neurons from slices removed at 24 hr post-hypoxic
seizures. GABA-evoked currents were measured from hippocampal slices taken from rats (n=6) 24 hr after hypoxia-induced seizures. (A) Typical
examples of GABA-evoked currents in CA1 neurons at various holding potentials after application of phenobarbital (PB, 100 mM), and phenobarbital
in combination with bumetanide (PB+BM). Treatment effects were compared to normal conditions (HS) prior to drug administration. (B) Current–
voltage curves for the recordings shown in A. The data points were fitted with a straight line. (C) Summary of the reversal potential of GABA-evoked
currents under different recording conditions: control (HS, 258.6161.28 mV), phenobarbital only (PB, 258.4661.58 mV), and phenobarbital in
combination with bumetanide (PB+BM, 264.5362.30 mV). Error bars indicate SEM. *p,0.05.
doi:10.1371/journal.pone.0057148.g007
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bumetanide brain penetration, [54] as adult rats dosed with
0.3 mg/kg result in brain:serum ratios of approximately 0.007,
[23] comparable to the 0.007–0.009 ratio at 0.3 mg/kg dose we
report in P10 rats.
Lack of Adverse Effects on Constitutive Apoptosis with
Bumetanide Add-on Therapy
GABA agonists such as phenobarbital (at doses higher than
40 mg/kg [26]) and benzodiazepines, NMDA receptor antago-
nists, and the anticonvulsants including phenytoin, valproate, and
vigabatrin, can increase constitutive neuronal apoptosis when the
agents are delivered to immature rodents within the first two weeks
of life. [24,27,34] However, administration of other anticonvul-
sants such as topiramate and levetiracetam do not appear to elicit
these same side effects. [55,56] Similarly, we found no increase in
apoptotic neurons following administration of 15 mg/kg pheno-
barbital and 0.3 mg/kg bumetanide, either alone or in combina-
tion, to P10 rats. Interestingly, daily bumetanide treatment from
P7–P14 (the age range in the present study and analogous to term
human) [7] did not cause developmental delays in neurotransmis-
sion or alterations in anxiety or startle behavior, although
treatment prior to P7 did cause adverse effects. [37].
Conclusion
In light of the fact that bumetanide is currently under
investigation as an add-on therapy to phenobarbital in a neonatal
seizure Phase I/II trial, we show that doses of bumetanide similar
to those currently being tested in our human trial were indeed
effective in combination with phenobarbital in a rat model of
neonatal seizures, without any increases in neuronal apoptosis.
Effective doses were associated with a serum concentration of 100–
300 ng/ml, within the range previously shown to be tolerated by
human infants when administered for diuretic purposes. [20]
These findings provide preclinical translational data to support
ongoing clinical trials with bumetanide in neonatal seizures.
Supporting Information
Table S1 Serum and brain bumetanide levels, and
brain:serum ratio in littermate controls. Dose=bumeta-
nide dosage. Time=min after bumetanide injection. n=number
of rats. Concentrations (Conc.) are expressed as mean 6 SEM.
(DOCX)
Table S2 Serum and brain bumetanide levels, and
brain:serum ratio after hypoxic seizures. Dose=bumeta-
nide dosage. Time=min after bumetanide injection. n=number
of rats. Concentrations (Conc.) are expressed as mean 6 SEM.
(DOCX)
Methods S1.
(DOCX)
Acknowledgments
The authors wish to thank Griffin Boll and Annelise Joseph for technical
assistance during the earlier course of this study, and Dr. Kevin Staley for
helpful comments during manuscript preparation. The monoclonal T4
antibody, contributed by Christian Lytle and Bliss Forbush III, was
obtained from the Developmental Studies Hybridoma Bank developed
under the auspices of the NICHD and maintained by The University of
Iowa, Department of Biology, Iowa City, IA 52242.
Author Contributions
Conceived and designed the experiments: RC SM YL AR DT KTK MJ
SR GB FJ. Performed the experiments: RC TH SMM HS YL DMT KTK
MJ. Analyzed the data: RC TH SMM HS YL DMT KTK MJ.
Contributed reagents/materials/analysis tools: FEJ GB KTK. Wrote the
paper: RC TH SMM HS YL DMT KTK FEJ.
References
1. Ronen GM, Buckley D, Penney S, Streiner DL (2007) Long-term prognosis in
children with neonatal seizures: a population-based study. Neurology 69: 1816–
1822.
2. Sankar R, Painter MJ (2005) Neonatal seizures: After all these years we still love
what doesn’t work. Neurology 64: 776–777.
3. Scher MS, Alvin J, Gaus L, Minnigh B, Painter MJ (2003) Uncoupling of EEG-
clinical neonatal seizures after antiepileptic drug use. PediatrNeurol 28: 277–
280.
4. Glykys J, Dzhala VI, Kuchibhotla KV, Feng G, Kuner T, et al. (2009)
Differences in cortical versus subcortical GABAergic signaling: a candidate
mechanism of electroclinical uncoupling of neonatal seizures. Neuron 63: 657–
672.
5. Silverstein FS, Jensen FE (2007) Neonatal seizures. AnnNeurol 62: 112–120.
6. Jensen FE (2009) Neonatal seizures: an update on mechanisms and
management. Clin Perinatol 36: 881–900, vii.
7. Rakhade SN, Jensen FE (2009) Epileptogenesis in the immature brain: emerging
mechanisms. Nat Rev Neurol 5: 380–391.
8. Kahle KT, Staley KJ (2008) The bumetanide-sensitive Na-K-2Cl cotransporter
NKCC1 as a potential target of a novel mechanism-based treatment strategy for
neonatal seizures. Neurosurg Focus 25: E22.
9. Blaesse P, Airaksinen MS, Rivera C, Kaila K (2009) Cation-chloride
cotransporters and neuronal function. Neuron 61: 820–838.
10. Ben Ari Y (2002) Excitatory actions of gaba during development: the nature of
the nurture. NatRevNeurosci 3: 728–739.
11. Sipila ST, Huttu K, Yamada J, Afzalov R, Voipio J, et al. (2009) Compensatory
enhancement of intrinsic spiking upon NKCC1 disruption in neonatal
hippocampus. J Neurosci 29: 6982–6988.
12. Russell JM (2000) Sodium-potassium-chloride cotransport. Physiol Rev 80: 211–
276.
13. Galanopoulou AS (2008) Dissociated gender-specific effects of recurrent seizures
on GABA signaling in CA1 pyramidal neurons: role of GABA(A) receptors.
J Neurosci 28: 1557–1567.
14. Nunez JL, McCarthy MM (2007) Evidence for an extended duration of GABA-
mediated excitation in the developing male versus female hippocampus. Dev
Neurobiol 67: 1879–1890.
15. Rakhade SN, Klein PM, Huynh T, Hilario-Gomez C, Kosaras B, et al. (2011)
Development of later life spontaneous seizures in a rodent model of hypoxia-
induced neonatal seizures. Epilepsia 52: 753–765.
16. Dzhala VI, Brumback AC, Staley KJ (2008) Bumetanide enhances phenobar-
bital efficacy in a neonatal seizure model. AnnNeurol 63: 222–235.
17. Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, et al. (2005)
NKCC1 transporter facilitates seizures in the developing brain. NatMed 11:
1205–1213.
18. Ibla JC, Khoury J, Kong T, Robinson A, Colgan SP (2006) Transcriptional
repression of Na-K-2Cl cotransporter NKCC1 by hypoxia-inducible factor-1.
Am J Physiol Cell Physiol 291: C282–289.
19. Loscher W, Puskarjov M, Kaila K (2012) Cation-chloride cotransporters
NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepilepto-
genic treatments. Neuropharmacology.
20. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL (1996)
Pharmacokinetics of bumetanide in critically ill infants. Clin Pharmacol Ther
60: 405–413.
21. Lopez-Samblas AM, Adams JA, Goldberg RN, Modi MW (1997) The
pharmacokinetics of bumetanide in the newborn infant. Biol Neonate 72:
265–272.
22. Jensen FE, Applegate CD, Holtzman D, Belin T, Burchfiel J (1991)
Epileptogenic effect of hypoxia in the immature rodent brain. Annof Neurol
29: 629–637.
23. Li Y, Cleary R, Kellogg M, Soul JS, Berry GT, et al. (2011) Sensitive isotope
dilution liquid chromatography/tandem mass spectrometry method for
quantitative analysis of bumetanide in serum and brain tissue.
J Chromatogr B Analyt Technol Biomed Life Sci 879: 998–1002.
24. Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, et al. (2002) Antiepileptic
drugs and apoptotic neurodegeneration in the developing brain. ProcNatlA-
cadSciUSA 99: 15089–15094.
25. Ives JR (2005) New chronic EEG electrode for critical/intensive care unit
monitoring. JClinNeurophysiol 22: 119–123.
26. Bittigau P, Sifringer M, Ikonomidou C (2003) Antiepileptic drugs and apoptosis
in the developing brain. Ann N Y Acad Sci 993: 103–114; discussion 123–104.
Phenobarbital and Bumetanide in Neonatal Seizures
PLOS ONE | www.plosone.org 11 March 2013 | Volume 8 | Issue 3 | e5714827. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, et al. (1999) Blockade
of NMDA receptors and apoptotic neurodegeneration in the developing brain.
Science 283: 70–74.
28. Sherwood NM, Timiras PS (1970) A Stereotaxic Atlas of the Developing Rat
Brain. Univ. of Calif. Press: Berkeley.
29. Talos DM, Fishman RE, Park H, Folkerth RD, Follett PL, et al. (2006)
Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-pro-
pionic acid receptor subunit expression in forebrain and relationship to regional
susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and
cortex. J Comp Neurol 497: 42–60.
30. Jensen FE, Wang C, Stafstrom CE, Liu Z, Geary C, et al. (1998) Acute and
chronic increases in excitability in rat hippocampal slices after perinatal hypoxia
in vivo. JNeurophysiol 79: 73–81.
31. Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, et al. (2008) Early
alterations of AMPA receptors mediate synaptic potentiation induced by
neonatal seizures. J Neurosci 28: 7979–7990.
32. Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, et al. (2012) Altered
inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol 71:
539–551.
33. Brandt C, Nozadze M, Heuchert N, Rattka M, Loscher W (2010) Disease-
modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the
pilocarpine model of temporal lobe epilepsy. J Neurosci 30: 8602–8612.
34. Olney JW (2003) Excitotoxicity, apoptosis, and neuropsychiatric disorders.
Current Opinion in Pharmacology 3: 101–109.
35. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, et al. (1999)
Phenobarbital compared with phenytoin for the treatment of neonatal seizures.
NEnglJMed 341: 485–489.
36. Volpe JJ (2008) Neurology of the newborn. Philadelphia: Saunders/Elsevier. xiv,
1094 p. p.
37. Silverstein FS, Jensen FE, Inder T, Hellstrom-Westas L, Hirtz D, et al. (2008)
Improving the treatment of neonatal seizures: National Institute of Neurological
Disorders and Stroke workshop report. J Pediatr 153: 12–15.
38. Cha BH, Silveira DC, Liu X, Hu Y, Holmes GL (2002) Effect of topiramate
following recurrent and prolonged seizures during early development. Epilepsy
Res 51: 217–232.
39. Aujla PK, Fetell M, Jensen FE (2009) Talampanel suppresses the acute and
chronic effects of seizures in a rodent neonatal seizure model. Epilepsia In Press.
40. Koh S, Jensen FE (2001) Topiramate blocks perinatal hypoxia-induced seizures
in rat pups an attenuates the subsequent susceptibility to seizures and neuronal
injury. Neurology 53: S07.002.
41. Rossetti F, Rodrigues MC, de Oliveira JA, Garcia-Cairasco N (2006) EEG
wavelet analyses of the striatum-substantia nigra pars reticulata-superior
colliculus circuitry: audiogenic seizures and anticonvulsant drug administration
in Wistar audiogenic rats (War strain). Epilepsy Res 72: 192–208.
42. Mazarati A, Shin D, Sankar R (2009) Bumetanide inhibits rapid kindling in
neonatal rats. Epilepsia 50: 2117–2122.
43. White A, Williams PA, Hellier JL, Clark S, Edward Dudek F, et al. EEG spike
activity precedes epilepsy after kainate-induced status epilepticus. Epilepsia 51:
371–383.
44. Raol YH, Lapides DA, Keating JG, Brooks-Kayal AR, Cooper EC (2009) A
KCNQ channel opener for experimental neonatal seizures and status
epilepticus. Ann Neurol 65: 326–336.
45. Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, et al. (2012) The
Interaction Between Early Life Epilepsy and Autistic-Like Behavioral Conse-
quences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway.
PLoS One 7: e35885.
46. Liu Y, Shangguan Y, Barks JD, Silverstein FS (2012) Bumetanide augments the
neuroprotective efficacy of phenobarbital plus hypothermia in a neonatal
hypoxia-ischemia model. Pediatr Res 71: 559–565.
47. Lemonnier E, Ben-Ari Y (2010) The diuretic bumetanide decreases autistic
behaviour in five infants treated during 3 months with no side effects. Acta
Paediatr 99: 1885–1888.
48. Rivera C, Voipio J, Kaila K (2005) Two developmental switches in GABAergic
signalling: the K+-Cl- cotransporter KCC2 and carbonic anhydrase CAVII.
JPhysiol 562: 27–36.
49. Sipila ST, Schuchmann S, Voipio J, Yamada J, Kaila K (2006) The cation-
chloride cotransporter NKCC1 promotes sharp waves in the neonatal rat
hippocampus. J Physiol 573: 765–773.
50. Dzhala VI, Kuchibhotla KV, Glykys JC, Kahle KT, Swiercz WB, et al. (2010)
Progressive NKCC1-dependent neuronal chloride accumulation during neona-
tal seizures. J Neurosci 30: 11745–11761.
51. Bragin DE, Sanderson JL, Peterson S, Connor JA, Muller WS (2009)
Development of epileptiform excitability in the deep entorhinal cortex after
status epilepticus. Eur J Neurosci 30: 611–624.
52. Flemmer AW, Gimenez I, Dowd BF, Darman RB, Forbush B (2002) Activation
of the Na-K-Cl cotransporter NKCC1 detected with a phospho-specific
antibody. J Biol Chem 277: 37551–37558.
53. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL (1996) Dose-
ranging evaluation of bumetanide pharmacodynamics in critically ill infants.
Clin Pharmacol Ther 60: 424–434.
54. Feit P (1990) Bumetanide: historical background, taxonomy and chemistry. In:
Landt A, editor. Bumetanide. Camford, UK: Marius. 1–13.
55. Kim JS, Kondratyev A, Tomita Y, Gale K (2007) Neurodevelopmental impact
of antiepileptic drugs and seizures in the immature brain. Epilepsia 48 Suppl 5:
19–26.
56. Glier C, Dzietko M, Bittigau P, Jarosz B, Korobowicz E, et al. (2004)
Therapeutic doses of topiramate are not toxic to the developing rat brain.
ExpNeurol 187: 403–409.
Phenobarbital and Bumetanide in Neonatal Seizures
PLOS ONE | www.plosone.org 12 March 2013 | Volume 8 | Issue 3 | e57148